Drug Discovery 시장 규모, 점유율, 성장 분석 : 약제 유형별, 기술별, 프로세스별, 최종사용자별, 지역별 - 산업별 예측(2024-2031년)
Drug Discovery Market Size, Share, Growth Analysis, By Drug Type (Small Molecule Drugs, Biologic Drugs), By Technology (High Throughput Screening (HTS), Pharmacogenomics), By Process, By End User, By Region - Industry Forecast 2024-2031
세계의 Drug Discovery 시장 규모는 2022년에 957억 달러로 평가되며, 2023년 1,020억 2,000만 달러에서 2031년에는 1,701억 1,000만 달러로 성장하며, 예측 기간(2024-2031년)의 CAGR은 6.6%로 성장할 전망입니다.
세계의 Drug Discovery 시장은 질병의 만연, 기술의 진보, 맞춤형 의료에 대한 수요 증가에 의해 지원되며 대폭적인 성장이 전망되고 있습니다. 혁신적인 R&D 구상은 질병 메커니즘을 규명하고 신약개발을 간소화하기 위해 유전체, 단백질체학, 계산생물학을 통합한 다학제적 접근법을 통해 새로운 신약 타깃과 효과적인 치료법에 초점을 맞추었습니다. 또한 고성능 스크리닝, 인공지능, 빅데이터 분석 등 첨단 기술을 활용하여 의약품 개발의 효율성과 성공률을 크게 향상시킬 수 있습니다. 정밀의료와 표적치료에 대한 관심이 높아짐에 따라 향후 수년간 시장이 크게 확대될 것으로 예상되며, 의료분야의 중요한 진입장벽으로 자리매김할 것으로 보입니다.
목차
서론
조사 방법
- 정보 조달
- 2차 데이터와 1차 데이터 방법
- 시장 규모 예측
- 시장의 전제조건과 제한
개요
- 세계 시장 전망
- 공급과 수요의 동향 분석
- 부문별 기회 분석
시장 역학과 전망
- 시장 개요
- 시장 규모
- 시장 역학
- Porter의 산업 분석과 영향
- 경쟁 기업 간 경쟁 관계
- 대체품의 위협
- 바이어의 교섭력
- 신규 진출업체의 위협
- 공급 기업의 교섭력
주요 시장 인사이트
- 주요 성공 요인
- 경쟁의 정도
- 주요 투자 기회
- 시장 에코시스템
- 시장의 매력 지수(2023년)
- PESTEL 분석
- 거시경제 지표
- 밸류체인 분석
- 가격 분석
- 규제 상황
- 특허 분석
Drug Discovery 시장 규모 : 약제 유형별 & CAGR(2024-2031년)
Drug Discovery 시장 규모 : 기술별 & CAGR(2024-2031년)
- 시장 개요
- 고성능 스크리닝(HTS)
- 약물유전체학
- Combinatorial Chemistry
- 나노 기술
- 기타
Drug Discovery 시장 규모 : 프로세스별 & CAGR(2024-2031년)
- 시장 개요
- 대상 선택
- 리드 최적화
- 히트부터 리드까지의 식별
Drug Discovery 시장 규모 : 최종사용자별 & CAGR(2024-2031년)
- 시장 개요
- 제약회사
- 계약 연구기관(CRO)
- 학술연구기관
- 기타
Drug Discovery 시장 규모 & CAGR(2024-2031년)
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
- GCC 국가
- 남아프리카공화국
- 기타 중동 및 아프리카
경쟁 정보
- 상위 5사의 비교
- 주요 기업의 시장 포지셔닝(2023년)
- 주요 시장 기업이 채택한 전략
- 시장의 최근 동향
- 기업의 시장 점유율 분석(2023년)
- 주요 기업의 기업 개요
- 제품 포트폴리오 분석
- 부문별 점유율 분석
- 매출의 전년대비 비교(2021-2023년)
주요 기업 개요
- Pfizer Inc.
- Novartis AG
- Merck & Co., Inc.
- Johnson & Johnson
- Roche Holding AG
- Sanofi S.A.
- GlaxoSmithKline plc
- AstraZeneca plc
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- AbbVie Inc.
- Amgen Inc.
- Bayer AG
- Takeda Pharmaceutical Company Limited
- Gilead Sciences, Inc.
- Biogen Inc.
- Boehringer Ingelheim GmbH
- Vertex Pharmaceuticals Incorporated
- Regeneron Pharmaceuticals, Inc.
- Novo Nordisk A/S
결론과 권장사항
KSA
Global Drug Discovery Market size was valued at USD 95.70 billion in 2022 and is poised to grow from USD 102.02 billion in 2023 to USD 170.11 billion by 2031, growing at a CAGR of 6.6% during the forecast period (2024-2031).
The Global Drug Discovery market is poised for substantial growth, fueled by rising disease prevalence, technological advancements, and a heightened demand for personalized medicine. Innovative R&D initiatives are focusing on novel drug targets and effective therapeutics, with an interdisciplinary approach that incorporates genomics, proteomics, and computational biology to unravel disease mechanisms and streamline drug discovery. Furthermore, the utilization of cutting-edge technologies such as high-throughput screening, artificial intelligence, and big data analytics significantly improves the efficiency and success rates of drug development. As the emphasis on precision medicine and targeted therapies intensifies, the market is set for remarkable expansion in the upcoming years, positioning it as a key player in the healthcare landscape.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Drug Discovery market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Drug Discovery Market Segmental Analysis
Global Drug Discovery Market is segmented by drug type, technology, process, end user and region. Based on drug type, the market is segmented into small molecule drugs and biologic drugs. Based on technology, the market is segmented into high throughput screening (HTS), pharmacogenomics, combinatorial chemistry, nanotechnology and other. Based on process, the market is segmented into target selection, lead optimization and hit-to-lead identification. Based on end user, the market is segmented into pharmaceutical companies, contract research organizations (CROs), academic and research institutes and other. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Drug Discovery Market
A key driver of the Global Drug Discovery market is the escalating prevalence of chronic and infectious diseases. The growing rates of conditions such as cancer, cardiovascular diseases, and various infectious illnesses have intensified the demand for innovative and effective pharmaceutical solutions. This surge in disease incidence compels pharmaceutical companies and research institutions to prioritize investment in drug discovery and development efforts, accelerating the creation of new treatments and therapies to address these pressing health challenges. As a result, the landscape of drug discovery is becoming increasingly vital in the quest for improved healthcare outcomes and enhanced patient well-being worldwide.
Restraints in the Global Drug Discovery Market
The Global Drug Discovery market faces significant restraints primarily due to the high costs and the lengthy nature of the drug development process. The journey from drug discovery to market approval is intricate and resource-intensive, necessitating considerable investments in research, clinical trials, and navigating regulatory requirements. This complexity, coupled with stringent safety and efficacy standards, extends development timelines and inflates overall expenses. As a result, these factors can hinder the accessibility and affordability of innovative medications, creating challenges for stakeholders involved in the drug discovery process and potentially impacting the market's growth trajectory.
Market Trends of the Global Drug Discovery Market
In the Global Drug Discovery market, a significant trend is the escalating integration of artificial intelligence (AI) and machine learning (ML) technologies, catalyzing a transformative shift in the drug development landscape. These innovative technologies facilitate the rapid analysis of extensive biological datasets, allowing for precise identification of drug-target interactions and streamlined workflows. AI-driven virtual screening and molecular modeling not only enhance the efficiency of drug candidate identification but also reduce overall costs and timelines associated with the drug discovery process. As a result, this trend is poised to improve success rates in clinical trials and foster the emergence of novel therapeutics, ultimately reshaping the pharmaceutical industry's approach to drug development.
Table of Contents
Introduction
- Objectives of the Study
- Scope of the Report
- Definitions
Research Methodology
- Information Procurement
- Secondary & Primary Data Methods
- Market Size Estimation
- Market Assumptions & Limitations
Executive Summary
- Global Market Outlook
- Supply & Demand Trend Analysis
- Segmental Opportunity Analysis
Market Dynamics & Outlook
- Market Overview
- Market Size
- Market Dynamics
- Driver & Opportunities
- Restraints & Challenges
- Porters Analysis & Impact
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers
Key Market Insights
- Key Success Factors
- Degree of Competition
- Top Investment Pockets
- Market Ecosystem
- Market Attractiveness Index, 2023
- PESTEL Analysis
- Macro-Economic Indicators
- Value Chain Analysis
- Pricing Analysis
- Regulatory Landscape
- Patent Analysis
Global Drug Discovery Market Size by Drug Type & CAGR (2024-2031)
- Market Overview
- Small Molecule Drugs
- Biologic Drugs
Global Drug Discovery Market Size by Technology & CAGR (2024-2031)
- Market Overview
- High Throughput Screening (HTS)
- Pharmacogenomics
- Combinatorial Chemistry
- Nanotechnology
- Other
Global Drug Discovery Market Size by Process & CAGR (2024-2031)
- Market Overview
- Target Selection
- Lead Optimization
- Hit-to-Lead Identification
Global Drug Discovery Market Size by End User & CAGR (2024-2031)
- Market Overview
- Pharmaceutical Companies
- Contract Research Organizations (CROs)
- Academic and Research Institutes
- Other
Global Drug Discovery Market Size & CAGR (2024-2031)
- North America (Drug Type, Technology, Process, End User)
- Europe (Drug Type, Technology, Process, End User)
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
- Asia-Pacific (Drug Type, Technology, Process, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Latin America, (Drug Type, Technology, Process, End User)
- Brazil
- Rest of Latin America
- Middle East & Africa (Drug Type, Technology, Process, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2023
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2023
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2021-2023)
Key Company Profiles
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Roche Holding AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol-Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Gilead Sciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biogen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Boehringer Ingelheim GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Vertex Pharmaceuticals Incorporated
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Regeneron Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novo Nordisk A/S
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendation
